Phase II Study of Revlimid [lenalidomide], Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma.

Trial Profile

Phase II Study of Revlimid [lenalidomide], Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Prednisone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Dec 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 07 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top